There is a relative lack of PD-L1-based regimens for melanoma patients, so we introduced a dataset of uroepithelial carcinoma treated with atezolizumab, but we still hope that the m6Sig score system can be analyzed and validated in melanoma immunotherapy with different immune checkpoint inhibitors. The gene discussed is CD274; the disease is urothelial carcinoma.